Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John M Wentworth

Showing results (1-10 of 104) with videos related to

Pageof 11
Sort By:
Internal Medicine Journal|September 6, 2024
Resolution of symptoms of binge eating disorder associated with semaglutide treatment for obesity and type 1 diabetesJoanna Y Gong, John M Wentworth
The Journal of Clinical Endocrinology and Metabolism|June 8, 2007
Does insulin resistance need resistin?John M Wentworth, Leonard C Harrison
Diabetes, Obesity & Metabolism|February 21, 2020
The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placebo-controlled trialJohn M Wentworth, Peter G Colman,
Nature Reviews. Endocrinology|July 29, 2009
Reappraising the stereotypes of diabetes in the modern diabetogenic environmentJohn M Wentworth, Spiros Fourlanos, Leonard C Harrison
Diabetes Research and Clinical Practice|March 27, 2012
Body mass index correlates with ischemic heart disease and albuminuria in long-standing type 2 diabetesJohn M Wentworth, Spiros Fourlanos, Peter G Colman
Internal Medicine Journal|November 20, 2020
Glycaemic trajectory and predictors of suboptimal glycaemic control in people with type 2 diabetesNipuni P Pathiraja, Peter G Colman, John M Wentworth
Metabolism Open|August 20, 2020
A pilot study of the feasibility of empagliflozin in recent-onset type 1 diabetesJohn M Wentworth, Spiros Fourlanos, Peter G Colman, et al.
Diabetes Care|April 10, 2025
M120 Risk Score Improves Identification of Children at High Risk of Developing Clinical Type 1 Diabetes and Reports Short-Term Response to Preventive ImmunotherapyMinh V Le, Leonard C Harrison, Tim Spelman, et al.
Diabetes Care|October 30, 2025
Incidence of Type 2 Diabetes With Verapamil Compared With Other Calcium Channel BlockersJulian W Sacre, John M Wentworth, Dianna J Magliano, et al.
Diabetes Care|May 27, 2025
β-Cell Function Derived From Routine Clinical Measures Reports and Predicts Treatment Response to Immunotherapy in Recent-Onset Type 1 DiabetesMichelle So, Sara Vogrin, Michaela Waibel, et al.
Pageof 11

Showing results (1-10 of 104) with videos related to

Sort By:
Pageof 11
Internal Medicine Journal|September 6, 2024
Resolution of symptoms of binge eating disorder associated with semaglutide treatment for obesity and type 1 diabetesJoanna Y Gong, John M Wentworth
The Journal of Clinical Endocrinology and Metabolism|June 8, 2007
Does insulin resistance need resistin?John M Wentworth, Leonard C Harrison
Diabetes, Obesity & Metabolism|February 21, 2020
The methionine aminopeptidase 2 inhibitor ZGN-1061 improves glucose control and weight in overweight and obese individuals with type 2 diabetes: A randomized, placebo-controlled trialJohn M Wentworth, Peter G Colman,
Nature Reviews. Endocrinology|July 29, 2009
Reappraising the stereotypes of diabetes in the modern diabetogenic environmentJohn M Wentworth, Spiros Fourlanos, Leonard C Harrison
Diabetes Research and Clinical Practice|March 27, 2012
Body mass index correlates with ischemic heart disease and albuminuria in long-standing type 2 diabetesJohn M Wentworth, Spiros Fourlanos, Peter G Colman
Internal Medicine Journal|November 20, 2020
Glycaemic trajectory and predictors of suboptimal glycaemic control in people with type 2 diabetesNipuni P Pathiraja, Peter G Colman, John M Wentworth
Metabolism Open|August 20, 2020
A pilot study of the feasibility of empagliflozin in recent-onset type 1 diabetesJohn M Wentworth, Spiros Fourlanos, Peter G Colman, et al.
Diabetes Care|April 10, 2025
M120 Risk Score Improves Identification of Children at High Risk of Developing Clinical Type 1 Diabetes and Reports Short-Term Response to Preventive ImmunotherapyMinh V Le, Leonard C Harrison, Tim Spelman, et al.
Diabetes Care|October 30, 2025
Incidence of Type 2 Diabetes With Verapamil Compared With Other Calcium Channel BlockersJulian W Sacre, John M Wentworth, Dianna J Magliano, et al.
Diabetes Care|May 27, 2025
β-Cell Function Derived From Routine Clinical Measures Reports and Predicts Treatment Response to Immunotherapy in Recent-Onset Type 1 DiabetesMichelle So, Sara Vogrin, Michaela Waibel, et al.
Pageof 11